Literature DB >> 20458030

Raising the bar of efficacy for drug approval requires an understanding of patient diversity.

Marc L Berger, Stephen Eck, Stephen J Ruberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20458030     DOI： 10.1200/JCO.2010.28.2475

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.

Authors:  J Stuart Ferriss; Youngchul Kim; Linda Duska; Michael Birrer; Douglas A Levine; Christopher Moskaluk; Dan Theodorescu; Jae K Lee
Journal:  PLoS One       Date:  2012-02-10       Impact factor: 3.240

Review 2.  Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?

Authors:  Courtney Davis
Journal:  Soc Sci Med       Date:  2014-12-02       Impact factor: 4.634

3.  Annexin A3 Is a Potential Predictor of Platinum Resistance in Epithelial Ovarian Cancer Patients in a Prospective Cohort.

Authors:  Ying Jin; Li-Ping Feng; Xiang Jiang; Yong-Xue Wang; Jie Yin; Zi-Ping Yang; Yan Li; Ling-Ya Pan
Journal:  J Cancer       Date:  2015-06-10       Impact factor: 4.207
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.